Get notified when TVRD files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company lists its ability to continue as a going concern as a forward-looking risk, indicating substantial doubt about its ability to continue operations.
Tvardi Therapeutics launches at-the-market offering of up to $9.7M at $3.08/share
Filed July 17, 2026 · ~1 min read
Key Changes
-
high
Tvardi may sell up to $9,689,765 of common stock in an at-the-market offering through JonesTrading, with 3,146,027 shares assumed at $3.08.
The Offering verify on EDGAR → -
high
Net proceeds to the company are $9.4M after commissions and expenses; proceeds are for general corporate purposes.
Use of Proceeds verify on EDGAR → -
high
New investors would experience immediate dilution of $0.91 per share based on the assumed offering price.
Dilution verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SPWH 10-Q) is open in full — no account needed.
Partner
Trade TVRD commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify